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Abstract 
Merkel’s cell carcinoma is a rare cutaneous
tumor that can affect a wide variety of sites
throughout the body. Commonly, it affects the
skin  alone  and  the  management  of  limited
disease can be confusing since the natural
history of the disease involves distant metas-
tasis. Traditional management has required
wide local excision with negative margins of
resection.  We  describe  a  case  treated  with
local therapy alone and review the literature
to suggest that complete microscopic excision
may not be required if adjuvant radiotherapy
is used.
Case Report
A 74 year old Caucasian male presented with
a change in a skin lesion of the dorsal aspect
of the left forearm. A small non-descript lesion
of approximately 1.0 cm had been present for
at least 10 years  which began to grow signifi-
cantly over a six month period developing an
erythematous and more nodular appearance.
The patient was then referred for a surgical
opinion  and  excisional  biopsy.  The  original
gross pathology described a firm, tan-appear-
ing lesion measuring approximately 1.0 cm in
greatest  dimension.  The  original  interpreta-
tion  at  an  outside  institution  was  that  of
metastatic  anaplastic  carcinoma.  The  patho-
logic  slides  and  blocks  were  sent  to  the
Allegheny General Hospital and reviewed. The
tumor exhibited prominent peri-nuclear stain-
ing  for  cytokeratin  20,  strongly  positive  for
cytokeratin CAM 5.2, focally positive for neu-
ron specific enolase, synaptophysin and MAP
2. The tumor cells were negative for chromo-
granin, leukocyte common antigen, and cytok-
eratin 7. The margins of resection were micro-
scopically positive in multiple areas (R1 resec-
tion). The final diagnosis was neuroendocrine
(Merkel cell) carcinoma. At follow-up clinical
examination, no evidence of gross disease in
the  local  site  was  identified.  The  incision
measured 4.0 cm and was healing well. There
was a moderate amount of induration in the
peri-incisional area and minimal erythema in
the post-operative bed. The patient was reluc-
tant  to  undergo  additional  surgical  excision
due  to  the  likelihood  of  tissue  graft  or  flap
requirement and the resultant possibilities of
cosmetic  and  functional  deficit  in  order  to
cover  the  projected  large  skin  defect.  The
remainder of the physical exam was benign.
A metastatic workup consisting of a bone
scan,  CT  scan  of  the  chest  and  a  PET  scan
revealed no evidence of metastatic disease. A
brain MRI was normal. An abdominal CT scan
demonstrated evidence of a right-sided renal
mass  which  was  suggestive  of  an  angiomy-
olipoma.  An  ultrasound  of  the  kidneys  con-
firmed this finding.  After further questioning,
the patient admitted to a CT of the abdomen
done 7 years prior. We retrieved this scan and
found  that  the  lesion  was  unchanged.
Comprehensive metabolic analysis (CMP) and
hemogram were unremarkable. His past histo-
ry  revealed  hypertension,  gastro-esophageal
reflux, and benign prostatic hyperplasia. His
medications  included  tamsulosin  0.4  mg,
aspirin 81 mg, and esomeprazole 20 mg daily.
His family history was unremarkable as was
his review of systems, although he did admit to
a 50 pack year smoking history which ceased
10 years prior to diagnosis. 
The patient’s case was discussed in a multi-
disciplinary tumor board and the final decision
was made for local irradiation only in view of
the small, single focus of disease and complete
gross excision. The local therapy consisted of
shrinking  field  radiotherapy  begun  4  weeks
post-operatively. The tumor bed received 4600
cGy at 200 cGy per fraction including a 2.5 cm
margin followed by a boost delivering an addi-
tional 1400 cGy at 200 cGy per fraction to the
same site with a 1.5 cm margin. All treatment
was delivered with a 6 MV linear accelerator
using  three-dimensional  conformal  tech-
niques with a 1.0 tissue equivalent bolus over-
lying the incision to deliver full dose to the
skin  at  this  site.  Acute  treatment  related
sequelae included only grade II erythema of
the skin (CTCAE v 4.0)1 which resolved two
weeks following the completion of radiothera-
py. Follow up consisted of interim clinical his-
tory and complete physical examination and
repeat bone scan, CT scan of the brain, thorax,
and abdomen as well as a hemogram and CMP
on an every three month basis for two years.
PET scanning was repeated after the first fol-
low-up visit and then at 3 month intervals for
the same period of time. The patient is now 7
years post therapy and has had no evidence of
recurrence. His only treatment related seque-
lae is slightly increased fibrosis in the tumor
bed and permanent alopecia of the local site. 
Discussion
Natural history
Merkel cell carcinoma (MCC) is a rare and
often lethal cutaneous malignancy which was
first  described  in  1972.2 It  is  thought  to  be
derived from Merkel cells of the skin, but it has
also been proposed that the cell of origin may
be a primitive pluripotent epidermal cell.3 The
University  of  Pittsburgh  has  shown  that
Merkel  cell  carcinomas  frequently  harbor  a
polyomavirus  which  has  been  aptly  named
Merkel  cell  polyomavirus.4 The  exact  onco-
genic role of the virus remains to be clearly
elucidated. 
The incidence in the United States is 0.23
per  100,000  in  Caucasians,  occurring  most
commonly  in  the  elderly,  with  a  three-fold
increased incidence since 1986.5 MCC is much
less prevalent in the black population,6 and is
significantly  higher  in  immuno-suppressed
populations.    The  relative  risks  when  com-
pared  to  the  general  population  for  patients
with  HIV  or  those  who  have  received  organ
transplantation are 13.4 and 5, respectively.7,8
MCC typically presents as a firm, pinkish-
red nodular or plaque-like exophytic mass. The
most  common  locations  are  in  sun-exposed
skin of the head, neck or extremities.9 Wide
local excision is the mainstay of treatment,10
although radiotherapy has often been used as
adjuvant  or  definitive  treatment.11-15 As  with
melanoma, depth of invasion is a prognostic
feature.16 A recent meta-analysis also showed
the prognostic importance of sentinel lymph
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node  biopsy  (SLNB).  In  122  patients,  MCC
recurred within 3 years in 60% of patients with
a positive SLNB versus 20% having negative
nodes.17MCC is locally aggressive, demonstrat-
ing  local  recurrence  rates  between  25  and
100% following surgical excision and the mor-
tality rate of MCC is between 30 and 60%.9 In a
series  of  251  patients  from  one  institution,
patients with stage IV disease had a median
survival time of 6.8 months.18
Pathologic features
MCC appears as a dense population of small,
round  blue  cells  on  hematoxylan  and  eosin
stain. The nuclei are large relative to the cyto-
plasm and they may have finely granular and
evenly distributed chromatin (salt and pepper
like) (Figure A). Mitotic figures and apoptotic
cells  are  common.18 The  cells  form  dermal
nests, trabeculae or sheets. Mitotic activity is
usually brisk and single cell necrosis is fre-
quent  (Figure  B).  Immunohistochemistry
(IHC) is helpful to distinguish it from other
small cell types of malignancy such as small
cell lung carcinoma, lymphoma and melanoma.
Neuron-specific  enolase,  chromogranin,
synaptophysin and cytokeratin are frequently
positive in MCC. S-100 and thyroid transcrip-
tion factor-1 are negative in MCC, which help
distinguish it from small cell-lung carcinoma.
Cytokeratin 20 is a fairly specific and sensitive
marker for MCC, with a characteristic paranu-
clear dot-like positivity (Figure C).
Traditional management
Traditional management has been surgical
resection  as  the  mainstay  of  local  therapy.
However; standardized adjuvant therapy is less
well defined. In the largest reported study to
date,  the  Trans-Tasman  Radiation  Oncology
Group  reported  their  phase  II  findings  in
2003.(19) The standardized treatment consist-
ed  of  Carboplatinum  (day  1)  and  Etoposide
(days 1-3) with concurrent radiotherapy (5000
cGy at 200 cGy/fx with wide margins) followed
by two additional cycles of chemotherapy. Of
the 53 patients enrolled in the study 76% were
alive at 3 years and 65% had no evidence of
relapse.  Unfortunately  grade  III  neutropenia
occurred  in  57%  of  patients  and  23%  of
patients developed grade III skin toxicity. The
NCCN has incorporated this treatment strate-
gy as one recommended option for therapy.20 In
general,  the  recommendations  call  for  wide
surgical excision.10 One group reported on the
use of Moh’s micrographic surgery in highly
selected small MCC without adjuvant therapy
and reported a 96% local control rate and 5 year
overall survival rates approaching 80%.21 Three
patients had in-transit metastases while only
one patient developed a marginal recurrence
which was successfully salvaged with re-exci-
sion and local irradiation.
Radiotherapy as monotherapy
Radiotherapy  has  become  a  mainstay  of
local  treatment  with  most  reported  series
demonstrating  significant  increases  in  local
control with the addition of radiotherapy fol-
lowing surgical resection.22-27Although a single
study showed no improvement in local control,
a  small  sample  size  has  limited  the  conclu-
sion.18
Conflicting data have been reported regard-
ing the use of primary radiotherapy absent sur-
gical resection. In a series by Meeuwissen et
al.,28 7  of  80  total  patients  were  treated  by
radiotherapy  after  incomplete  gross  surgical
resection (R2 disease).  Six of these patients
recurred  with  primary  radiotherapy  alone
using  doses  of  4500-6000  cGy.  However;
Mortier  et al.29 have reported on a series of 9
patients  treated  with  primary  radiotherapy
(median dose 6000 cGy; range 5000- 7800 cGy)
with  no  local  recurrences  despite  primary
tumor sizes ranging from 1.0-8.0 cm.
Waiting  time  has  been  implicated  in  pro-
gression of disease. Tsang et al have reported
a near doubling of local recurrences (25 vs.
40%) when mean waiting times between sur-
gery and radiotherapy increased  from a mean
of 19 vs. 30 days respectively.30
Novel therapies
The use of imiquimod (an immune modula-
tor that activates TLR7 cells on the skin sur-
face) cream plus radiotherapy (5040 cGy in 28
fractions) has been used anecdotally31 as has
hyperthermia with radiotherapy32 with limited
success. Both groups demonstrated local con-
trol, however adjuvant radiotherapy was deliv-
ered in both cases and the margins of resec-
tion were histologically negative.
Conclusions
Conventional  local  treatment  of  MCC  has
traditionally involved wide local excision with
a goal to achieve negative surgical margins fol-
lowed by radiation therapy.  Depending upon
location, such surgical management can result
in significant disfigurement requiring recon-
structive flap or graft surgeries.  Additionally,
the  increased  time  interval  between  repeat
surgical and adjuvant management may wors-
en outcomes. The data we have presented here
demonstrate options for management that may
not require such extensive surgical approach-
es  or  microscopically  negative  margins  and
still result in satisfactory outcomes.   The case
we have presented is an example where radio-
therapy  following  surgery  for  a  small  tumor
resulted in local disease control with accept-
able  morbidity  despite  microscopic  marginal
positivity.  We urge consideration of such alter-
natives in cases where patients do not desire
additional potential disfiguring surgery. 
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